ºù«ÍÞÊÓƵ reported third-quarter results, delivering another quarter of consistent, high-quality performance. Organic1 sales growth for the underlying base business2 was 7.5%. Reported sales increased 6.9%. Adjusted diluted earnings per share (EPS) was $1.30 (GAAP diluted EPS was $0.94). We reaffirmed our full-year 2025 guidance, maintaining the organic sales growth range of 7.5% to 8.0%3 for the underlying base business and the EPS midpoint. We narrowed the EPS guidance range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.
Worldwide sales for the quarter totaled $11.4 billion, with multiple business segments driving performance. Medical Devices achieved double-digit growth for the 11th consecutive quarter, generating $5.4 billion in sales—an organic increase of 12.5% (14.8% reported). Five segments within Medical Devices delivered double-digit organic growth in the third quarter, including:
Sales of continuous glucose monitors were up 17.2% on an organic basis (20.5% reported) for a total of $2.0 billion.
Established Pharmaceuticals sales increased 7.1% on an organic basis (7.5% reported), with 11.1% organic growth in our key emerging markets, led by double-digit growth in several countries across Asia, Latin America and the Middle East. Nutrition sales growth was led by 5.4% organic growth (5.8% reported) in Adult Nutrition, driven by strong demand for Ensure® and Glucerna®.
In the third quarter, we made meaningful progress on key initiatives—advancing innovation, strengthening execution and deepening impact. Highlights included:
For full financial data and reconciliation of non-GAAP measures, you can read ºù«ÍÞÊÓƵ’s full .
For more information, view a summary of ºù«ÍÞÊÓƵ’s earnings highlights and download it here.
References
1 Organic sales growth excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business.
2Â Excludes the impact of COVID-19 testing sales.
3 ºù«ÍÞÊÓƵ has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact ºù«ÍÞÊÓƵ’s results in accordance with GAAP.Â
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. ºù«ÍÞÊÓƵ cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect ºù«ÍÞÊÓƵ's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. ºù«ÍÞÊÓƵ undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Important safety information
For U.S. important safety information about TriClip, visit:
Rx Only
NAVITORâ„¢ TRANSCATHETER AORTIC VALVE IMPLANTATION SYSTEM
INDICATIONS
The Navitor™ Transcatheter Aortic Valve Implantation System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).
CONTRAINDICATIONSÌýÌý
The valve is contraindicated for patients with inability to tolerate antiplatelet/anticoagulant therapy or nitinol alloy (nickel and titanium), or who have active infections, including endocarditis.
POTENTIAL ADVERSE EVENTSÂ
Adverse events potentially associated with the use of transcatheter bioprosthetic heart valves include but are not limited to: access site complications (e.g., pain, bleeding, infection, hematoma, pseudoaneurysm, etc.); acute coronary obstruction; acute myocardial infarction; allergic reaction to antiplatelet agents, contrast medium, or valve components; aortic rupture; ascending aorta trauma; atrio-ventricular node block; cardiac arrhythmias; conduction system injury; conversion to open surgical procedure; death; dissection; embolism; emergent balloon valvuloplasty; emergent percutaneous coronary intervention (PCI); emergent surgery (i.e., coronary artery bypass, heart valve replacement); endocarditis; explantation; heart failure; hemodynamic compromise; hemolysis; hemolytic anemia; hemorrhage; hypotension or hypertension; infection; myocardial ischemia; mitral valve insufficiency; multi-organ failure; non-structural dysfunction (i.e., entrapment by pannus, paravalvular leak, inappropriate sizing or positioning); pannus; pericardial effusion; perforation of the myocardium, ventricle, or a blood vessel; permanent disability; permanent pacemaker; regurgitation; renal insufficiency or renal failure; reoperation; respiratory failure; sepsis; stroke; structural deterioration (i.e., calcification, leaflet tear); thrombosis; tamponade; transfusion; valve embolization or migration; vessel dissection or spasm.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Share